Global Gonorrhea Treatment Market Report and Forecast 2024-2032

Global Gonorrhea Treatment Market Outlook

The global gonorrhea treatment market was estimated to be worth USD 1.48 billion in 2023. The market is likely to grow at a rate of 4.7% in the forecasted period 2024-2032. Within this growth rate, the market value is estimated to reach about USD 2.24 billion by 2032. The market is primarily driven by the increased prevalence of sexually transmitted infections and the expected launch of novel therapies.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Gonorrhea Treatment Market Insights: Causes, Symptoms, Diagnosis, Treatment, and Segmentation

Gonorrhea is a very common sexually transmitted infection caused by the bacterium Neisseria gonorrheae. The bacteria enter through different modes, such as anus, mouth, vagina, and penis. The gonorrhea is mainly spread through sexual fluids such as semen and vaginal fluid. Gonorrhea is caused by oral sex, intercourse, anal sex, or sharing sex toys with the infected person.

Gonorrhea is the second most common sexually transmitted infection, with around 1.14 million new gonorrhea infections being diagnosed in the United States every year. Most of the infections occur in people of the age group 15-24 years. 

The gonorrheal symptoms vary in men and women and depend on the severity of the disease. The common symptoms witnessed in women are increased vaginal discharge, lower abdominal pain, irregular bleeding between periods, and sexual intercourse pain.

The symptoms reported in men are white or yellow penis discharge, testicular pain, severe pain and burning. The common signs and symptoms of all genders are itchy feeling, soreness, trouble swallowing, itching, anal discharge, and poop difficulty.

The diagnosis of gonorrhea is done by performing a pelvic exam, testing a fluid sample from the penis, and urine sample analysis. The treatment is primarily done through antibiotics and other medications. Palliative care has been an important therapeutic intervention in the management of gonorrhea.

According to the global gonorrhea treatment market research report, the market can be categorised into the following segments:

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Market Breakup by Indication Type

• Uncomplicated Gonococcal Infection

• Gonococcal Arthritis

• Gonococcal Meningitis and Endocarditis

• Others

Market Breakup by Drug Category

• Macrolide Antibiotics
  • Azithromycin
• Third-Generation Cephalosporins
  • Cefixime
  • Cefotaxime
  • Ceftizoxime
  • Ceftriaxone
  • Cetriaxone
• Tetracycline Antibiotics
  • Doxycycline
• Fluoroquinolones Antibiotics
  • Gemifloxacin
• Aminoglycosides
  • Gentamicin
• Aminocyclitols
  • Spectinomycin
• Others

Market Breakup by Therapeutics

• Monotherapy

• Dual Therapy

• Others

Gonorrhea Treatment Market Breakup by Diagnosis Methods

• Nucleic Acid Amplification
• Gram Stain
• Enzyme-linked Immunosorbent Assay
• Gonorrhea Culture and Rapid Test
• Others

Market Breakup by Route of Administration

• Oral
• Injectable
• Others

Market Breakup by Region

• North America
  • United States of America
  • Canada
• Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Others
• Asia Pacific
  • China
  • Japan
  • India
  • ASEAN
  • Australia
  • Others
• Latin America
  • Brazil
  • Argentina
  • Mexico
  • Others
• Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Nigeria
  • South Africa
  • Others

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Market Scenario

The growth of the gonorrhea treatment market is primarily driven by the rising prevalence and incidence of gonorrhea, the introduction of national screening programs and growing awareness among the general population. 

According to the Centres for Disease Control and Prevention, nearly 700,000 novel cases of gonorrhea are diagnosed annually across the world. Thus, with the growing incidence of sexually transmitted infections, the market is anticipated to grow positively during the forecast period.

The introduction of technologically advanced tools for diagnosing bacterial growth and the concentration of lesions is anticipated to attribute to the increased patient pool. This has led to the increased demand for novel therapeutics, which will bolster the growth of the market.

Additionally, with the increasing resistance to the available antibiotics, there is a need for the discovery of novel medications. This is expected to aid the expansion of the gonorrhea treatment market owing to the novel product approvals and launches. Further, the growing research and developmental activities and the rising number of prescription drugs are fuelling the market growth.

Recent Market Trends: Based on Therapy and Region

Dual therapy is anticipated to dominate the market during the forecast period due to its rising adoption and better therapeutic efficacy than monotherapy. Additionally, the dual therapy of azithromycin and ceftriaxone is considered a first-line treatment for the management of gonorrhea. 

North America is anticipated to hold the largest share of the gonorrhea treatment market. This growth can be attributed to the advanced healthcare infrastructure and easy accessibility to novel technologies. Further, the increasing disease burden and the growing number of mergers and acquisitions among the key players are expected to augment the market growth in this region. 

Therapeutic Landscape

The therapeutic interventions incorporated in gonorrhea management depend on the age and gender of the patient. The treatment regimen generally involves the administration of antibiotics that aid in the slower progression of the disease by inhibiting the bacterial growth.

Treatment for Adults and Children

The rising cases of gonorrhea are leading to the growth of the gonorrhea treatment market. The treatment for adult gonorrhea patients involves the treatment with specific antibiotics that possess bacterial inhibition and thus, help in disease management. The commonly used antibiotic, ceftriaxone is being given as an injection in combination with oral azithromycin for the first-line treatment of asymptomatic gonorrhea. In case of intolerance to cephalosporin antibiotics, the combination of injectable gentamicin with oral azithromycin is considered.

Gonorrhea treatment should be received by both partners, irrespective of whether the partner is exhibiting any symptoms or not. The same diagnostic and therapeutic regimen is followed for both partners to prevent the disease in the future.

The treatment for new-born babies who had gotten the infection through their mothers is also diagnosed with the help of antibiotics.

Despite the availability of novel antibiotics, new strains of the bacteriae are developing resistance against these antibiotics, and hence, preventative care is essential to eradicate this problem. Safe sex needs to be practised from avoiding gonorrhea again and again in the further years.

Clinical Trials Landscape of the Gonorrhea Treatment Market

Over the last few decades, there has been a discovery of novel antibiotics for the treatment of symptomatic and asymptomatic gonorrhea. These medications can be administered orally or parenterally. 

However, with the rapid mutations, the bacterial strains keep mutating and eventually develop resistance against the antibiotics. Therefore, clinical researchers are tremendously working on developing novel therapeutic agents that could aid in disease management. 

Further, the treatment does not ensure the recurrence of the disease, hence scientists are also conducting clinical trials for the discovery of a gonorrheal vaccine that will act as a preventative measure and will prevent the disease occurrence.

Undergoing Clinical Trials For Novel Antibiotics and Vaccines in the Gonorrhea Treatment Market

Evoform Biosciences, a key market player is conducting the EVOGUARD clinical trials for the novel agent, EVO100, for the management and prevention of gonorrhea in women.

A dutch biotechnological company, Intravacc, has also initiated the Phase I clinical trials for its novel vaccine, NGoXIM. This vaccine has been developed by incorporating the outer membrane vesicles that possess immune-stimulating properties. The vaccine is expected to show a promising effect in the treatment of gonorrhea.

Several diagnostic systems are also under investigation, and once approved can aid in the faster and more accurate detection of gonorrhea disease. Lucina Health, a major pharmaceutical company, is testing its novel assay systems that are expected to augment the market growth. The investigational instrument incorporates both Chlamydia trachomatis and Neisseria gonorrheae assays that will provide the diagnosis with an overall accuracy of nearly 98 per cent.

These novel targeted therapies seem to grab the attention of key companies and investors, which will directly influence the development of this sector. This will help enable patient access and the growth of the market.

Competitive Landscape

The report gives an in-depth analysis of the key players involved in the gonorrhea treatment market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:

• Hologic, Inc.

• Danaher

• BD (Becton, Dickinson and Company)

• Teligent

• GSK plc

• Abbott

• Lupin Pharmaceuticals, Inc.

• Novartis AG

• Bayer AG

• F. Hoffmann-La Roche Ltd

• Pfizer Inc.

Key Highlights of the Report